2010's Top Biopharma Dealmakers
Executive Summary
Generics, emerging markets, orphan diseases and earn-out heavy M&A were the recurring dealmaking themes in 2010. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as the therapeutic categories that grabbed the most attention.